Summary

In PARTNER [NCT00530894; Leon MB et al. N Engl J Med 2010] Cohort A, transcatheter aortic valve implantation (TAVI) was shown to be noninferior to surgical aortic valve replacement (SAVR) for 1-year mortality in patients who were at high surgical risk. There were differences in procedure-related complications and valve performance at 1 year, with some endpoints favoring TAVI and others favoring SAVR. These alternative treatments have an impact on health-related quality of life from the perspective of the patient.